DONATE

Controlling brain states with a ray of light 

A study led by researchers from IBEC and IDIBAPS achieves, for the first time, the control of brain state transitions using a molecule responsive to light, named PAI.  The results not only pave the way to act on the brain patterns activity, but they also could lead to the development of photomodulated drugs for the treatment of brain lesions or diseases such as depression, bipolar disorders or Parkinson’s or Alzheimer’s diseases. 

New molecules allow to switch on and off neuronal circuits using light

Researchers from IBEC, in collaboration with an international team, describe the first molecules capable of regulate glycine receptors with light: Glyght and Azo-NZ1. The new molecules are a promising way to study neuronal circuits, to develop drug-based phototherapies non-invasively, and to understand neurological disorders related with the incorrect functioning of glycine receptors, as hyperekplexia, epilepsy and autism.

IBEC participates in European Project developing new technologies for the study and treatment of neurological diseases

Pau Gorostiza and his team at IBEC participates in the DEEPER project which aims at creating new tools for accessing the deep brain with unprecedented precision for the study and treatment of neurological diseases. The project involves 12 partners in 8 countries, and it has been funded by the European Union with approximately 5.7 million euros for the next 4 years.

Lights, Cells, Action! IBEC develops small molecules able to control endocytosis with light

IBEC’s research group “Nanoprobes and nanoswitches” creates a system based on light to inhibit the endocytocis and control its spatio-temporal dynamics. The newly developed light-sensitive small-molecule inhibitors of endocytosis (called dynazos) are water-soluble, cell permeable, photostable, and enable fast photoswitchable inhibition of endocytosis. This technology will allow more accurate and controlled studies were endocytosis is crucial, as in cellular grow, differentiation and motility.

New chemical lego blocks for health solutions

IBEC researchers develop new multi-responsive molecules able to self-assemble in water forming fiber-like structures. The so-called discotic molecules show responsiveness to temperature, light, pH, and ionic strength and they might show great potential for medical applications such as drug delivery systems, diagnosis or tissue engineering.

Edgar Fuentes is a PhD student in the Nanoscopy for Nanomedicine Group led by Lorenzo Albertazzi at the Institute for Bioengineering of Catalonia (IBEC). Within this group, Edgar and his colleagues focus on the synthesis of novel smart supramolecular materials for drug delivery.

Rossella Castagna, postdoctoral researcher at IBEC wins the ISOP2019 prize

Rossella Castagna a postdoctoral researcher in the Nanoprobes and Nanowitches group at IBEC was awared with the ISOP2019 prize last week 9th International Symposium on Photochromism held in Paris. This recognition comes from her contribution to the field of photochromism and for the results that were collectively obtained in their group in the field of photopharmacology.

Rossella presented the group results on photoswitchable drugs at the reference international meeting for photochromism, held every 3 years, where she was awarded with the conference prize. According to the organizing committee, such a prize rewards the most talented young researchers whose contribution is expected to notably impact the field of photochromism.

Three researchers from IBEC awarded with grants from “la Caixa” for their pioneering and high social impact research

José Antonio del Río, Pau Gorostiza, and Samuel Sánchez have been awarded in two of the “la Caixa” calls.

José Antonio del Río, principal investigator of the Molecular and Cellular Neurobiotechnology Group at IBEC, is one of the winners of the second edition of the call for applications in biomedicine and health. Del Río’s project focuses on analysing the molecular mechanisms involved in the genesis and propagation of tau protein in brain cells. This protein is linked with several neurodegenerative processes and is present in numerous diseases such as Alzheimer’s.

Pau Gorostiza, principal investigator of the Nanoprobes and Nanoswitches Group, also received an award at the second edition of the call for applications for research projects in biomedicine and health. In this case, for his project on degenerative eye conditions such as retinitis pigmentosa, which causes blindness due to the progressive degeneration of the cones and rods, which are the light sensitive cells.